Monitoring on the safety of 13-valent pneumococcal conjugate vaccine in Hebei Province
Objective To analyze the occurrence features of adverse events following immunization(AEFI)of 13-valent pneumococcal conjugate vaccine(PCV13)in Hebei Province,and to evaluate the vaccine's safety.Methods AEFI cases related to vaccination of PCV13 in Hebei Province from January 1,2020 to December 31,2022 were collected from AEFI Information Management System,China Information System for Disease Control and Prevention,and the incidence of reported AEFI cases was analyzed.Results The total reported incidence rate of AEFI of PCV13 was 37.24/100,000 doses.The incidence rate of adverse reactions was 36.84/100,000 doses,among which the incidence rate of common adverse reactions was 36.31/100,000 doses,and the incidence rate of rare adverse reactions 0.27/100,000 doses.Most of the reported AEFI cases caused by PCV13 were common adverse reactions,which occurred mainly within 24 hours after vaccination,and the overall regression was positive.Conclusion Up to now,13-valent pneumococcal conjugate vaccines used in Hebei Province are safe,and the incidence rate of rare adverse reactions is extremely low.
13-valent pneumococcal conjugate vaccineadverse events following immunizationpassive surveillance
NETL
NSTL
万方数据
